Key regions: France, India, United Kingdom, South Korea, Japan
Multiple Sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system. It is a rare disease in Belize, with an estimated prevalence of fewer than 10 cases per 100,000 people. However, the demand for MS drugs in the country has been steadily increasing in recent years.
Customer preferences: Belizeans with MS prefer to use drugs that are effective in reducing the frequency and severity of symptoms such as fatigue, muscle weakness, and difficulty walking. They also prefer drugs that have few side effects and are affordable.
Trends in the market: The MS drugs market in Belize has been growing due to an increase in the number of diagnosed cases and an increase in awareness of the disease among healthcare professionals and the general public. The market is dominated by a few multinational pharmaceutical companies that offer a range of drugs, including disease-modifying therapies (DMTs) and symptom management drugs. The prices of these drugs are high, and most patients rely on government subsidies or private insurance to cover the cost.
Local special circumstances: Belize has a small population and a limited healthcare budget. This has resulted in challenges in providing adequate healthcare services and drugs to the population, including those with MS. The country also faces logistical challenges in distributing drugs to remote areas of the country.
Underlying macroeconomic factors: The Belizean economy has been growing steadily in recent years, with a focus on tourism, agriculture, and offshore banking. However, the country still faces challenges such as high poverty rates, income inequality, and a lack of infrastructure. These factors can affect access to healthcare services and drugs, including MS drugs.In conclusion, the MS drugs market in Belize is growing due to an increase in diagnosed cases and awareness of the disease. However, the market is dominated by multinational pharmaceutical companies, and the high cost of drugs remains a challenge for most patients. Belize's small population and limited healthcare budget also present challenges in providing adequate healthcare services and drugs to the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
